M K PROTEINS

Date: 23.05.2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051
NSE SYMBOL: MKPL

Subject: Submission of Integrated Filing (Financial) for the Quarter and year ended 31st March, 2025

Dear Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated Filing (Financial) for the Quarter and year ended 31st March, 2025.

The same will be also available on the website of the Company at www.mkproteins.in.
Please take the above on your records.

Thanking you,

Yours Sincerely,
FOR M K PROTEINS LIMITED

NEHA AGGARWAL
Digitally signed by NEHA AGGARWAL
Date: 2025.05.23 17:24:52 +05'30'

Neha Aggarwal
Company Secretary cum Compliance Officer

M K PROTEINS

FORMAT FOR QUARTERLY INTEGRATED FILING (FINANCIAL)

A. FINANCIAL RESULTS

The financial results are the same as filed by the Company with the stock exchanges, a copy of which is attached herewith as an Annexure.

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable.

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Not applicable as there are no outstanding default on loans and debt securities as of 31st March 2025.

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (APPLICABLE ONLY FOR HALF-YEARLY FILINGS i.e., 2ND AND 4TH QUARTER)

Disclosed separately in XBRL

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED SEPARATELY) (APPLICABLE ONLY FOR ANNUAL FILING i.e., 4TH QUARTER)

Not Applicable.

NEHA AGGARWAL

Digitally signed by NEHA AGGARWAL
Date: 2025.05.23 17:25:37 +05'30'

M K PROTEINS

Date:
23.05.2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051
NSE SYMBOL: MKPL

Sub: Declaration under Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016

Dear Sir/Madam,

I, Parmod Kumar, Managing Director of M/s M K Proteins Limited, having its Registered Office at Naraingarh Road, Vill. Garnala Ambala City-134003 HR, hereby declare that **M/s KRA&CO.**, Statutory Auditors of the Company have issued an Auditor Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2025.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide its Circular No. Cir CFD CMD 56 2016 dated May 27, 2016.

Thanking You,

Yours Faithfully,
For M K Proteins Limited

M/s M. K. PROTEINS LTD AMBALA CITY (Haryana)

Parmod Kumar
Managing Director
DIN: 00126965

K R A & CO.
Chartered Accountants
011 - 47082855
Fax: 011 - 47082855
H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE ANNUAL FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF M. K. PROTEINS LIMITED

Opinion

We have audited the accompanying standalone annual financial results of **M. K. PROTEINS LIMITED** ("the company") for the half year and year ended March 31, 2025 ("Standalone annual Financial results") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and Board of Directors are responsible for the preparation of these standalone annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and

maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Companies Act 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

For KRA & Co.
Chartered Accountants
(Firm Registration No.020266N)

Rajat Goyal Digitally signed by Rajat Goyal

Rajat Goyal
Partner
Membership No.: 503150
UDIN: 25503150BMJBZH8774
Place: New Delhi
Date: 23-05-2025

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2025

(Rs. In Lacs)

		QUARTER ENDED			YEAR ENDED	
		31-03-2025 (AUDITED)	31-12-2024 (UNAUDITED)	31-03-2024 (AUDITED)	31-03-2025 (AUDITED)	31-03-2024 (AUDITED)
1.	**Revenue**					
a)	Revenue from Operation (Net)	13720.41	3947.88	8687.29	26770.60	24557.11
b)	Other Income	1.94	24.56	41.04	47.66	44.66
	Sub-Total "1"	13722.35	3972.44	8728.33	26818.26	24601.77
2.	**Expenditure**					
a)	Cost of Material Consumed	11229.32	2003.69	11144.47	16674.36	20571.80
b)	Purchase of Stock-in-Trade	2343.13	1968.15	358.70	5149.41	3294.36
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(1176.68)	(472.85)	(3985.10)	2146.27	(2223.11)
d)	Employees Benefits Expenses	82.49	63.97	79.26	274.52	278.80
e)	Manufacturing, Operating and Other Expenses	776.29	205.26	247.67	1282.93	973.61
f)	Finance Costs	67.44	6.92	39.77	110.50	106.49
g)	Depreciation and Amortization Expenses	8.85	11.43	17.76	35.17	52.85
	Sub-Total "2"	13330.84	3786.57	7902.53	25673.16	23054.80
3	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 – 2]	391.51	185.87	825.80	1145.10	1546.97
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) before Extraordinary items and Tax [3 – 4]	391.51	185.87	825.80	1145.10	1546.97
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before Tax [5 – 6]	391.51	185.87	825.80	1145.10	1546.97
8	**Tax Expenses**					
a)	Provision for Current Tax	111.54	47.40	236.15	301.86	417.73
b)	Provision for Deferred Tax Liability/(Adjustment)	0.36	0.95	6.67	3.50	8.05
c)	Prior Year Taxes	0.00	0.00	0.00	0.00	0.00
	Sub-Total "8"	111.90	48.35	242.82	305.36	425.78
9	Profit/(Loss) for the Period from continuing operations [7 - 8]	279.61	137.52	582.98	839.74	1121.19
10	Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
11	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00
12	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00
13	Profit/(Loss) for the period [9 + 12]	279.61	137.52	582.98	839.74	1121.19
14	**Other Comprehensive Income net of taxes**					
a)	(i) Amount of items that will not be reclassified to profit and loss	(1.51)	0.00	(0.55)	(1.51)	(0.55)
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	(0.38)	0.00	(0.14)	(0.38)	(0.14)
b)	(i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
	Sub- Total "14"	(1.13)	0.00	(0.41)	(1.13)	(0.41)
15	Total comprehensive Income for the Period [13 + 14]	278.48	137.52	582.57	838.61	1120.78
16	**Earnings per share**					
a)	Earnings per Equity Share for continuing operations					
	Basic earnings/(Loss) per share from continuing operations	0.07	0.04	0.16	0.22	0.30
	Diluted earning/(Loss) per share from continuing operations	0.07	0.04	0.16	0.22	0.30
b)	Earnings per Equity Share for discontinuing operations					
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00

M/s M. K. PROTEINS LTD. AMBALA CITY (Haryana)

c)	Earnings per Equity Share					
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.07	0.04	0.16	0.22	0.30
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.07	0.04	0.16	0.22	0.30
17	**Details of Equity Share Capital**					
	Paid-up Equity Share Capital	3753.72	3753.72	3753.72	3753.72	3753.72
	Face value of Equity Share Capital	1	1	1	1	1
18	Other Equity [Reserves]	3192.86	-	2353.84	3192.86	2353.84

Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 23rd May 2025.
2. The Statutory auditors of the Company have carried out an audit of the above results for the quarter and year to date ended March 31, 2025. The Auditors' opinion on quarterly and year to date standalone financial results of the company is unmodified.
3. Previous period/year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.
6. The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the year-to-date published figures up to the quarter ended December 31, 2024 and December 31, 2023 respectively.
7. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2025 is given as per Annexure "I" attached.

Place: Ambala

Dated: 23-05-2025

For and on behalf of the board

M/s M. K. PROTEINS LTD AMBALA CITY (Haryana)

(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

ANNEXURE "I"

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2025 IS GIVEN BELOW: -

	PARTICULARS	AS AT 31-03-2025 (AUDITED)	AS AT 31-03-2024 (AUDITED)
A	**ASSETS**		
1	**Non-Current Assets**		
	-Property, Plant and Equipment	285.74	189.69
	-Capital Work-in-Progress	665.54	590.00
	-Right of Use Assets	82.23	87.51
	-Intangible assets	0.00	0.00
	Financial Assets		
	-Investments	0.00	0.00
	-Other financial assets	34.26	44.50
	Deferred Tax Assets (net)	34.34	37.46
	Other non-current assets	103.30	91.34
	Sub-Total "1" Non-Current Assets	1205.41	1040.50
2	**Current Assets**		
	-Inventories	11132.48	7927.25
	Financial Assets		
	-Investments	0.00	0.00
	-Trade Receivables	140.33	357.27
	-Cash and Cash Equivalents	3.38	9.23
	-Other Financial assets	0.00	0.00
	Other Current Assets	575.37	290.35
	Sub-Total "2" Current Assets	11851.56	8584.41
	TOTAL ASSETS	**13056.97**	**9624.60**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	-Equity Share Capital	3753.72	3753.72
	-Other Equity	3192.86	2353.84
	Sub-Total "1" Total of Equity	6946.58	6107.56
2	**Liabilities**		
	Non-Current Liabilities		
	Financial Liabilities		
	-Borrowings	83.04	0.00
	-Lease Liabilities	94.91	97.19
	-Other financial liabilities	0.00	0.00
	Provisions	32.02	23.61
	Other non-current liabilities	0.00	0.00
	Sub-Total Non-Current Liabilities	209.97	120.80
	Current Liabilities		
	Financial Liabilities		
	-Borrowings	3692.12	1909.06
	-Lease Liabilities	2.28	2.07
	-Trade Payables	1931.46	1148.84
	-Other Financial Liabilities	37.68	30.23
	Other Current Liabilities	131.08	80.99
	Provisions	1.69	2.87
	Current Tax Liabilities (Net)	104.11	222.18
	Sub-Total Current Liabilities	5900.42	3396.24
	TOTAL EQUITY AND LIABILITIES	**13056.97**	**9624.60**

Place: Ambala

Dated: 23-05-2025

For and on behalf of the board

(Parmod Kumar)
Managing Director
DIN: 00126965

M/s M. K. PROTEINS LTD AMBALA CITY (Haryana)

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2025

	PARTICULARS		FOR THE HALF YEAR ENDED 31/03/2025 AUDITED	FOR THE YEAR ENDED 31/03/2024 AUDITED
A.	**CASH FLOW FROM OPERATING ACTIVITIES**			
	-Net Profit/(Loss) before tax		1145.10	1546.97
	-Adjustment for:-			
	Depreciation and amortisation expenses		35.17	52.85
	Interest Expenses		110.50	106.49
	Provision of allowances for Bad and Doubtful debts (Excepted credit loss allowance)		(1.80)	(33.32)
	Provision for Retirement Gratuity Benefit to Employees		4.79	3.57
	Net Gain on Sale/Fair Valuation of Investment on FVTPL		(45.86)	(3.62)
	Interest Income		0.00	(1.03)
	Loss on sale of Fixed Assets (Car)		2.86	0.00
	Operating profit before working capital changes		**1250.76**	**1671.91**
	Adjustment for (Increase)/Decrease in operating assets:			
	-Trade Receivables		218.74	1281.61
	-Inventories		(3205.24)	(806.75)
	-Other Non-Current Assets		(11.06)	(44.98)
	-Other Current Assets		(285.92)	835.52
	Adjustment for Increase/(Decrease) in operating Liabilities:			
	-Trade Payables		782.62	668.60
	-Other Financial Current liabilities		6.74	(8.20)
	-Other Current Liabilities		50.09	(4.77)
	-Provisions		0.00	0.00
	Cash use in / generated from operation		(1193.27)	3592.94
	-Direct taxes paid		(419.52)	(351.32)
	NET CASH FROM OPERATING ACTIVITIES		**(1612.79)**	**3241.62**
B.	**CASH FLOW FROM INVESTING ACTIVITIES**			
	-Sale Proceed of fixed assets		18.00	0.00
	-Sale Proceeds for Investment in Mutual Funds		1980.86	298.62
	-(Increase)/Decrease in Bank Balances not considered as Cash and Cash Equivalent		0.00	0.00
	-Purchase of Investment		(1935.00)	(295.00)
	-Fixed Assets/Capital Work in Progress Purchases		(222.33)	(590.33)
	-Other Non-Current Financial Asset (Securities)		10.23	(2.15)
	-Interest Income		0.00	1.03
	NET CASH FROM INVESTING ACTIVITIES		**(148.24)**	**(587.83)**

M/s M. K. PROTEINS LTD. AMBALA CITY (Haryana)